Large clinical trials can be particularly useful in the early treatment and prevention of neurodegenerative diseases because of the amount of data collected, though patient recruitment and retention are challenging, says biostatistician.
Schwarz Pharma's foray into the central nervous system
disorder market is beginning to pay serious dividends as the
firm's ground-breaking transdermal patch for Parkinson's continues
to prove a success story, now gaining...
Oxford Biomedica has made available preclinical efficacy data,
which suggests that gene-based product could have significant
efficacy for those suffering from Parkinson's disease when compared
to current treatment methods.